Therefore, antithrombotic prophylaxis in SVT, particularly in BCS, is an unmet clinical need and warrants prospective studies exploring the role of new direct oral anticoagulants38 and the new JAK2 inhibitors in MPN patients. The gene discussed is JAK2; the disease is myeloproliferative disorder.